Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCAB NASDAQ:CVKD NASDAQ:FRTX NASDAQ:LGVN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCABBioAtla$0.35-5.0%$0.41$0.24▼$2.53$20.56M0.91908,443 shs1.38 million shsCVKDCadrenal Therapeutics$11.29-4.9%$13.39$5.70▼$22.90$22.20M0.9543,711 shs26,107 shsFRTXFresh Tracks Therapeutics$0.94-0.5%$0.94$0.03▼$1.03$5.59M0.542,709 shs2,402 shsLGVNLongeveron$1.52-1.3%$1.34$1.14▼$4.29$22.69M0.21577,955 shs322,151 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCABBioAtla0.00%-8.21%-11.67%+8.71%-80.55%CVKDCadrenal Therapeutics0.00%-12.62%-15.68%-32.60%+1,128,999,900.00%FRTXFresh Tracks Therapeutics0.00%0.00%0.00%0.00%+1.63%LGVNLongeveron0.00%+7.04%+25.62%+4.11%-61.03%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCABBioAtla1.634 of 5 stars3.31.00.00.00.62.50.6CVKDCadrenal Therapeutics2.2082 of 5 stars3.53.00.00.00.61.70.6FRTXFresh Tracks TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ALGVNLongeveron2.8094 of 5 stars3.64.00.00.01.11.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCABBioAtla 2.50Moderate Buy$5.001,320.45% UpsideCVKDCadrenal Therapeutics 3.00Buy$32.00183.44% UpsideFRTXFresh Tracks Therapeutics 0.00N/AN/AN/ALGVNLongeveron 3.25Buy$8.67470.18% UpsideCurrent Analyst Ratings BreakdownLatest FRTX, CVKD, BCAB, and LGVN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/16/2025CVKDCadrenal TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.00(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCABBioAtla$11M1.87N/AN/A$0.25 per share1.41CVKDCadrenal TherapeuticsN/AN/AN/AN/A$4.17 per shareN/AFRTXFresh Tracks Therapeutics$10.06M0.56N/AN/A$1.66 per share0.56LGVNLongeveron$2.23M10.20N/AN/A$1.47 per share1.03Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCABBioAtla-$69.78M-$1.22N/AN/AN/AN/A-373.47%-116.55%8/6/2025 (Estimated)CVKDCadrenal Therapeutics-$10.65M-$9.26N/AN/AN/AN/A-244.94%-181.94%8/6/2025 (Estimated)FRTXFresh Tracks Therapeutics-$5.69M-$1.41N/A∞N/AN/AN/AN/AN/ALGVNLongeveron-$15.97M-$6.28N/AN/AN/A-760.72%-85.07%-70.74%8/13/2025 (Estimated)Latest FRTX, CVKD, BCAB, and LGVN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025BCABBioAtla-$0.29N/AN/AN/AN/AN/A8/13/2025Q2 2025LGVNLongeveron-$0.35N/AN/AN/A$0.41 millionN/A8/6/2025Q2 2025CVKDCadrenal Therapeutics-$1.60N/AN/AN/AN/AN/A5/8/2025Q1 2025CVKDCadrenal Therapeutics-$1.64-$2.09-$0.45-$2.09N/AN/A5/6/2025Q1 2025BCABBioAtla-$0.28-$0.29-$0.01-$0.26N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCABBioAtlaN/AN/AN/AN/AN/ACVKDCadrenal TherapeuticsN/AN/AN/AN/AN/AFRTXFresh Tracks TherapeuticsN/AN/AN/AN/AN/ALGVNLongeveronN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCABBioAtlaN/A2.352.35CVKDCadrenal TherapeuticsN/A4.324.32FRTXFresh Tracks TherapeuticsN/AN/AN/ALGVNLongeveronN/A5.615.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCABBioAtla77.23%CVKDCadrenal Therapeutics7.92%FRTXFresh Tracks Therapeutics25.04%LGVNLongeveron10.01%Insider OwnershipCompanyInsider OwnershipBCABBioAtla11.50%CVKDCadrenal Therapeutics48.62%FRTXFresh Tracks Therapeutics0.23%LGVNLongeveron11.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCABBioAtla6058.42 million51.70 millionOptionableCVKDCadrenal Therapeutics41.97 million1.01 millionNot OptionableFRTXFresh Tracks Therapeutics205.97 million5.96 millionNot OptionableLGVNLongeveron2014.93 million13.26 millionNot OptionableFRTX, CVKD, BCAB, and LGVN HeadlinesRecent News About These CompaniesLongeveron receives FDA approval for pediatric heart therapy INDJuly 10, 2025 | uk.investing.comLongeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric ... - Seeking AlphaJuly 10, 2025 | seekingalpha.comLongeveron Inc. Receives FDA Approval for IND Application to Advance Clinical Trial of Stem Cell Therapy for Pediatric Dilated Cardiomyopathy - NasdaqJuly 10, 2025 | nasdaq.comLongeveron Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM)July 9, 2025 | finanznachrichten.deLongeveron stock soars after FDA approves IND for heart failure treatmentJuly 9, 2025 | in.investing.comLGVN Announces Groundbreaking Treatment Approved for TrialJuly 9, 2025 | msn.comLongeveron Shares Jump as FDA Clears Phase 2 Trial for Pediatric Heart TherapyJuly 9, 2025 | msn.comLongeveron Inc. Receives FDA Approval for IND Application to Advance Clinical Trial of Stem Cell Therapy for Pediatric Dilated CardiomyopathyJuly 8, 2025 | quiverquant.comQLongeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM)July 8, 2025 | globenewswire.comLongeveron Inc. Appoints Than Powell as Chief Business Officer to Lead Partnering and International Strategy - NasdaqJune 28, 2025 | nasdaq.comLongeveron Inc. Appoints Than Powell as Chief Business Officer to Lead Partnering and International StrategyJune 26, 2025 | quiverquant.comQLongeveron® Appoints Than Powell as Chief Business OfficerJune 26, 2025 | globenewswire.comLGVN Announces Pivotal Test UpdateJune 24, 2025 | msn.comLongeveron Inc. Completes Enrollment for Phase 2b ELPIS II Trial Evaluating Laromestrocel for Hypoplastic Left Heart Syndrome, With Results Expected in Q3 2026June 24, 2025 | quiverquant.comQLongeveron® Announces Completion of Enrollment of Pivotal Phase 2b Clinical Trial Evaluating Laromestrocel as a Treatment for Hypoplastic Left Heart Syndrome (HLHS)June 24, 2025 | globenewswire.comLongeveron Inc. CEO Wa’el Hashad to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid ConferenceJune 11, 2025 | nasdaq.comLongeveron® to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid ConferenceJune 9, 2025 | globenewswire.comLongeveron Inc. (NASDAQ:LGVN) Director Sells $13,000.00 in StockJune 3, 2025 | insidertrades.comHere's Why Longeveron (NASDAQ:LGVN) Must Use Its Cash WiselyMay 29, 2025 | finance.yahoo.comLongeveron Inc. to Explore Partnership Opportunities for Alzheimer’s Stem Cell Therapy Program at BIO International ConventionMay 22, 2025 | nasdaq.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFRTX, CVKD, BCAB, and LGVN Company DescriptionsBioAtla NASDAQ:BCAB$0.35 -0.02 (-5.02%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$0.36 +0.01 (+2.27%) As of 07/18/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.Cadrenal Therapeutics NASDAQ:CVKD$11.29 -0.58 (-4.89%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$11.24 -0.05 (-0.44%) As of 07/18/2025 06:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.Fresh Tracks Therapeutics NASDAQ:FRTXFresh Tracks Therapeutics, Inc. does not have significant operations. Previously, the company was engaged in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.Longeveron NASDAQ:LGVN$1.52 -0.02 (-1.30%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$1.53 +0.01 (+0.66%) As of 07/18/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
